Cyclophosphamide
Breast Cancer
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07423611CT.gov ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07102940CT.gov Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07410559CT.gov Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07015853CT.gov ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | — | Not Yet Recruiting | — | — | — |
NCT07593820CT.gov A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. | — | Recruiting | — | — | — |
NCT07372079CT.gov Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy | — | Not Yet Recruiting | — | — | — |
NCT07432178CT.gov CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） | — | Not Yet Recruiting | — | — | — |
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT07317778CT.gov Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07486089CT.gov Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | — | Recruiting | — | — | — |
Show 481 more trialsShow fewer
NCT07510802CT.gov Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | — | Recruiting | — | — | — |
NCT07410494CT.gov Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06324240CT.gov Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06492759CT.gov High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07407920CT.gov Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | — | Active Not Recruiting | — | — | — |
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07016399CT.gov Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC | — | Recruiting | — | — | — |
NCT06959537CT.gov A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) | — | Recruiting | — | — | — |
NCT07107217CT.gov Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06606730CT.gov Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06996093CT.gov Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor | — | Not Yet Recruiting | — | — | — |
NCT06604858CT.gov Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT07137793CT.gov Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients | — | Recruiting | — | — | — |
NCT06802757CT.gov Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06876636CT.gov Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT07362914CT.gov Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions | — | Recruiting | — | — | — |
NCT06618287CT.gov A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05539365CT.gov Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT06402435CT.gov SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | — | Recruiting | — | — | — |
NCT06369285CT.gov A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06500208CT.gov Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | — | Recruiting | — | — | — |
NCT06341647CT.gov Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | — | Withdrawn | — | — | — |
NCT06513364CT.gov Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT05741164CT.gov Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06532812CT.gov TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer | — | Recruiting | — | — | — |
NCT06409390CT.gov Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | — | Recruiting | — | — | — |
NCT06470633CT.gov To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06535893CT.gov Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer | — | Recruiting | — | — | — |
NCT05485766CT.gov Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06347068CT.gov Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | — | Recruiting | — | — | — |
NCT06471673CT.gov A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | — | Recruiting | — | — | — |
NCT06253520CT.gov Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT06404463CT.gov QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06351332CT.gov ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | — | Terminated | — | — | — |
NCT06389006CT.gov To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | — | Recruiting | — | — | — |
NCT04102436CT.gov Non-Viral TCR Gene Therapy | — | Withdrawn | — | — | — |
NCT05756166CT.gov Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT06246968CT.gov A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | — | Recruiting | — | — | — |
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06144944CT.gov Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06186700CT.gov Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer | — | Completed | — | — | — |
NCT06072612CT.gov Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | — | Recruiting | — | — | — |
NCT06058377CT.gov Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | — | Recruiting | — | — | — |
NCT06103864CT.gov A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05491226CT.gov Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | — | Recruiting | — | — | — |
NCT06112379CT.gov A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05900206CT.gov Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT05318469CT.gov Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06010862CT.gov Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | — | Recruiting | — | — | — |
NCT06107673CT.gov Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | — | Recruiting | — | — | — |
NCT05673200CT.gov Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05929768CT.gov Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05678205CT.gov A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | — | Withdrawn | — | — | — |
NCT06227117CT.gov Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | — | Recruiting | — | — | — |
NCT05852691CT.gov A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05877599CT.gov A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | — | Recruiting | — | — | — |
NCT05914753CT.gov Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT05812807CT.gov Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | — | Recruiting | — | — | — |
NCT05256745CT.gov RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05876065CT.gov Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05673629CT.gov Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT05675579CT.gov A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | — | Active Not Recruiting | — | — | — |
NCT05422794CT.gov Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT05787587CT.gov A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT06009627CT.gov Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | — | Completed | — | — | — |
NCT04789096CT.gov Tucatinib Together With Pembrolizumab and Trastuzumab | — | Terminated | — | — | — |
NCT05959889CT.gov Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer | — | Completed | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06373744CT.gov Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients | — | Completed | — | — | — |
NCT04348747CT.gov Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | — | Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05645380CT.gov Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | — | Active Not Recruiting | — | — | — |
NCT05629585CT.gov A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | — | Active Not Recruiting | — | — | — |
NCT05093387CT.gov SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | — | Withdrawn | — | — | — |
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT05483491CT.gov KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | — | Recruiting | — | — | — |
NCT05491694CT.gov To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT04512261CT.gov TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | — | Withdrawn | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03492918CT.gov Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16) | — | Unknown | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05207514CT.gov Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | — | Terminated | — | — | — |
NCT05177796CT.gov Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT05112536CT.gov Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05287308CT.gov Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | — | Not Yet Recruiting | — | — | — |
NCT05163223CT.gov Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT05681728CT.gov A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT05203445CT.gov A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05233696CT.gov Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | — | Withdrawn | — | — | — |
NCT05159193CT.gov Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | — | Recruiting | — | — | — |
NCT05114720CT.gov Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | — | Completed | — | — | — |
NCT05159778CT.gov Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | — | Completed | — | — | — |
NCT05113251CT.gov Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04895761CT.gov Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT05728268CT.gov Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index | — | Recruiting | — | — | — |
NCT04137640CT.gov Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | — | Unknown | — | — | — |
NCT04639245CT.gov Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05165225CT.gov Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | — | Active Not Recruiting | — | — | — |
NCT05656079CT.gov To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | — | Unknown | — | — | — |
NCT04941885CT.gov Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer | — | Unknown | — | — | — |
NCT04717531CT.gov Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | — | Unknown | — | — | — |
NCT04683679CT.gov A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT04872985CT.gov Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04762901CT.gov LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | — | Withdrawn | — | — | — |
NCT04190056CT.gov Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | — | Terminated | — | — | — |
NCT03749850CT.gov Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer | — | Unknown | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04373031CT.gov Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04418219CT.gov Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT04683445CT.gov Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03841747CT.gov Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04293393CT.gov Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04448886CT.gov Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | — | Active Not Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT03982004CT.gov Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03988036CT.gov A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | — | Completed | — | — | — |
NCT04251169CT.gov Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression | — | Terminated | — | — | — |
NCT04468061CT.gov Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | — | Recruiting | — | — | — |
NCT04511871CT.gov A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT03971045CT.gov Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04389073CT.gov Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine | — | Unknown | — | — | — |
NCT04187898CT.gov Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | — | Completed | — | — | — |
NCT04290793CT.gov Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04348643CT.gov Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | — | Unknown | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04042701CT.gov DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05346107CT.gov PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT04335669CT.gov NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | — | Active Not Recruiting | — | — | — |
NCT04081389CT.gov Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03546686CT.gov Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04170465CT.gov Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO) | — | Completed | — | — | — |
NCT04066790CT.gov Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT04182568CT.gov Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer | — | Unknown | — | — | — |
NCT01907529CT.gov A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer | — | Unknown | — | — | — |
NCT03952325CT.gov Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | — | Terminated | — | — | — |
NCT03609047CT.gov Adjuvant Palbociclib in Elderly Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03894007CT.gov Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | — | Terminated | — | — | — |
NCT03742986CT.gov Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | — | Completed | — | — | — |
NCT03789097CT.gov Vaccination With Flt3L, Radiation, and Poly-ICLC | — | Completed | — | — | — |
NCT03644589CT.gov Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT04350021CT.gov Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03632941CT.gov A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | — | Terminated | — | — | — |
NCT03747120CT.gov Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | — | Active Not Recruiting | — | — | — |
NCT03726879CT.gov A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | — | Completed | — | — | — |
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03599453CT.gov Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT03725059CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | — | Active Not Recruiting | — | — | — |
NCT03756090CT.gov The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT03449238CT.gov Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | — | Recruiting | — | — | — |
NCT06190600CT.gov Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy | — | Active Not Recruiting | — | — | — |
NCT03285607CT.gov MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | — | Withdrawn | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT03435952CT.gov Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | — | Active Not Recruiting | — | — | — |
NCT03556358CT.gov Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | — | Completed | — | — | — |
NCT03493854CT.gov A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT03514121CT.gov FPA150 in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03289819CT.gov Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | — | Completed | — | — | — |
NCT03328026CT.gov Combination Study of SV-BR-1-GM With Retifanlimab | — | Completed | — | — | — |
NCT03428802CT.gov Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | — | Active Not Recruiting | — | — | — |
NCT03101748CT.gov Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03800836CT.gov A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT03225547CT.gov Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | — | Terminated | — | — | — |
NCT03393845CT.gov Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT03409198CT.gov Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | — | Completed | — | — | — |
NCT03197389CT.gov Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. | — | Completed | — | — | — |
NCT03366844CT.gov Breast Cancer Study of Preoperative Pembrolizumab + Radiation | — | Active Not Recruiting | — | — | — |
NCT03373708CT.gov Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | — | Unknown | — | — | — |
NCT03222856CT.gov Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes | — | Completed | — | — | — |
NCT03362060CT.gov PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03012230CT.gov Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03507465CT.gov Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT04659551CT.gov Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | — | Completed | — | — | — |
NCT03106415CT.gov Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03237572CT.gov Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03025035CT.gov Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | — | Completed | — | — | — |
NCT03095352CT.gov Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | — | Completed | — | — | — |
NCT03248427CT.gov Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. | — | Completed | — | — | — |
NCT02860000CT.gov Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | — | Completed | — | — | — |
NCT03025880CT.gov Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC | — | Completed | — | — | — |
NCT03139851CT.gov Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide | — | Completed | — | — | — |
NCT03164993CT.gov Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | — | Completed | — | — | — |
NCT02971761CT.gov Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT03051672CT.gov Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | — | Terminated | — | — | — |
NCT02953340CT.gov SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | — | Completed | — | — | — |
NCT03497702CT.gov Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | — | Unknown | — | — | — |
NCT03066947CT.gov SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT03356860CT.gov Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | — | Completed | — | — | — |
NCT02830724CT.gov Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | — | Recruiting | — | — | — |
NCT03012100CT.gov Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03051659CT.gov A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | — | Completed | — | — | — |
NCT02999477CT.gov A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | — | Completed | — | — | — |
NCT03032107CT.gov A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 | — | Completed | — | — | — |
NCT02971748CT.gov Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT02957968CT.gov Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | — | Active Not Recruiting | — | — | — |
NCT02954874CT.gov Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02914470CT.gov Carboplatin-cyclophosphamide Combined With Atezolizumab | — | Completed | — | — | — |
NCT01676753CT.gov Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | — | Completed | — | — | — |
NCT03123770CT.gov Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | — | Unknown | — | — | — |
NCT02789657CT.gov Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | — | Completed | — | — | — |
NCT02779751CT.gov A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02778685CT.gov Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02789332CT.gov Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency | — | Completed | — | — | — |
NCT03273595CT.gov Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT03202446CT.gov Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer | — | Terminated | — | — | — |
NCT02730130CT.gov Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT02792114CT.gov T-Cell Therapy for Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02752685CT.gov Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02742051CT.gov A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT02685059CT.gov Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02719691CT.gov Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | — | Completed | — | — | — |
NCT02790580CT.gov Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients | — | Unknown | — | — | — |
NCT02637375CT.gov A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02593227CT.gov Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02694224CT.gov Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT02692742CT.gov Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia | — | Completed | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02643420CT.gov SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) | — | Completed | — | — | — |
NCT02605915CT.gov Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT02561832CT.gov A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer | — | Terminated | — | — | — |
NCT02627248CT.gov Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT02630368CT.gov A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) | — | Unknown | — | — | — |
NCT02499367CT.gov Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | — | Unknown | — | — | — |
NCT02447003CT.gov Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | — | Completed | — | — | — |
NCT03576521CT.gov Evaluation of Ocoxin®-Viusid® in Breast Cancer | — | Completed | — | — | — |
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT03017404CT.gov A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer | — | Completed | — | — | — |
NCT02457650CT.gov T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | — | Unknown | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02187991CT.gov Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT02229084CT.gov Vaccination of High Risk Breast Cancer Patients | — | Completed | — | — | — |
NCT02339532CT.gov Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | — | Completed | — | — | — |
NCT02219789CT.gov Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02276300CT.gov HER2-Peptide Vaccination of Patients With Solid Tumors | — | Completed | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT01646034CT.gov High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02215876CT.gov Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | — | Withdrawn | — | — | — |
NCT02153905CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | — | Terminated | — | — | — |
NCT02214381CT.gov A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response | — | Completed | — | — | — |
NCT02018458CT.gov Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer | — | Completed | — | — | — |
NCT02299999CT.gov SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02365805CT.gov Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer | — | Completed | — | — | — |
NCT01964391CT.gov A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT02111850CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | — | Completed | — | — | — |
NCT01966471CT.gov A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | — | Completed | — | — | — |
NCT02842099CT.gov Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer | — | Unknown | — | — | — |
NCT01996267CT.gov Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | — | Active Not Recruiting | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
NCT01639911CT.gov Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01898117CT.gov Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01910870CT.gov Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes | — | Terminated | — | — | — |
NCT01597414CT.gov Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | — | Completed | — | — | — |
NCT02980965CT.gov Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT01818063CT.gov Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | — | Completed | — | — | — |
NCT02897700CT.gov A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | — | Recruiting | — | — | — |
NCT02527746CT.gov Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | — | Completed | — | — | — |
NCT01705691CT.gov Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT01593020CT.gov Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | — | Completed | — | — | — |
NCT01606241CT.gov Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01622361CT.gov Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | — | Unknown | — | — | — |
NCT01564056CT.gov Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment | — | Active Not Recruiting | — | — | — |
NCT01554371CT.gov Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT02001519CT.gov Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy | — | Completed | — | — | — |
NCT01611051CT.gov A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01697293CT.gov PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | — | Terminated | — | — | — |
NCT01516307CT.gov Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects | — | Completed | — | — | — |
NCT01526512CT.gov Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01526499CT.gov Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01503905CT.gov Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | — | Unknown | — | — | — |
NCT01537536CT.gov Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT01498588CT.gov Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01501487CT.gov MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | — | Completed | — | — | — |
NCT01985841CT.gov Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer | — | Terminated | — | — | — |
NCT01421017CT.gov Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | — | Completed | — | — | — |
NCT01433562CT.gov Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients | — | Completed | — | — | — |
NCT01351909CT.gov Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01378533CT.gov The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC | — | Unknown | — | — | — |
NCT01220128CT.gov Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | — | Terminated | — | — | — |
NCT01660542CT.gov An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01304797CT.gov Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT02119715CT.gov A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01612247CT.gov Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy | — | Unknown | — | — | — |
NCT01205217CT.gov Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | — | Withdrawn | — | — | — |
NCT01229605CT.gov Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT01199432CT.gov Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer | — | Completed | — | — | — |
NCT01008150CT.gov Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01205503CT.gov Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release | — | Completed | — | — | — |
NCT01540110CT.gov Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses | — | Completed | — | — | — |
NCT01270373CT.gov NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? | — | Unknown | — | — | — |
NCT01131195CT.gov Metronomic Therapy in Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT01105650CT.gov Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01147016CT.gov Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery | — | Terminated | — | — | — |
NCT01210768CT.gov A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients | — | Unknown | — | — | — |
NCT01314833CT.gov Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy | — | Completed | — | — | — |
NCT00856492CT.gov S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01022138CT.gov Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT01067989CT.gov Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01415336CT.gov AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer | — | Unknown | — | — | — |
NCT01057069CT.gov Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01530607CT.gov Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer | — | Completed | — | — | — |
NCT00925548CT.gov STRIDE - STimulating Immune Response In aDvanced brEast Cancer | — | Terminated | — | — | — |
NCT01120171CT.gov Myocet Plus Endoxan for Older Patients With Breast Cancer | — | Terminated | — | — | — |
NCT00976131CT.gov Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer | — | Completed | — | — | — |
NCT01321775CT.gov Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer | — | Unknown | — | — | — |
NCT00852332CT.gov Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer | — | Terminated | — | — | — |
NCT01006785CT.gov Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00971737CT.gov Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00849472CT.gov Treatment With Pazopanib for Neoadjuvant Breast Cancer | — | Completed | — | — | — |
NCT00866905CT.gov Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer | — | Completed | — | — | — |
NCT00832338CT.gov Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores | — | Terminated | — | — | — |
NCT01227408CT.gov Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | — | Withdrawn | — | — | — |
NCT00847444CT.gov Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention | — | Unknown | — | — | — |
NCT00841828CT.gov Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | — | Completed | — | — | — |
NCT00789581CT.gov A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT00847171CT.gov Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00712881CT.gov Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00777673CT.gov Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | — | Unknown | — | — | — |
NCT00791037CT.gov Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00756470CT.gov Phase II Neoadjuvant in Inflammatory Breast Cancer | — | Terminated | — | — | — |
NCT01090128CT.gov Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | — | Terminated | — | — | — |
NCT00795678CT.gov Chemotherapeutic Agents in Brain/Breast | — | Completed | — | — | — |
NCT00656669CT.gov Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer | — | Completed | — | — | — |
NCT00615901CT.gov Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00721747CT.gov Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer | — | Unknown | — | — | — |
NCT00574587CT.gov Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | — | Completed | — | — | — |
NCT00567554CT.gov Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | — | Completed | — | — | — |
NCT00455533CT.gov Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00553683CT.gov Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | — | Unknown | — | — | — |
NCT00630032CT.gov Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer | — | Completed | — | — | — |
NCT00434031CT.gov CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT00954135CT.gov Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients | — | Unknown | — | — | — |
NCT00538395CT.gov Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer | — | Unknown | — | — | — |
NCT01212887CT.gov Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | — | Terminated | — | — | — |
NCT00020722CT.gov Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT00524303CT.gov Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | — | Completed | — | — | — |
NCT00577122CT.gov Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00496665CT.gov ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer | — | Completed | — | — | — |
NCT00499603CT.gov Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | — | Unknown | — | — | — |
NCT00525759CT.gov Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer | — | Completed | — | — | — |
NCT00542191CT.gov Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | — | Terminated | — | — | — |
NCT00499122CT.gov NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | — | Completed | — | — | — |
NCT00429182CT.gov Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00513695CT.gov Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | — | Completed | — | — | — |
NCT00493649CT.gov Adj TC + Herceptin Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00544167CT.gov Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | — | Completed | — | — | — |
NCT00448266CT.gov Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | — | Terminated | — | — | — |
NCT00432172CT.gov Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT00470301CT.gov Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00436566CT.gov Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00482391CT.gov Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | — | Completed | — | — | — |
NCT00372424CT.gov Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | — | Completed | — | — | — |
NCT00381173CT.gov A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | — | Completed | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00404066CT.gov Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | — | Completed | — | — | — |
NCT00394251CT.gov Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | — | Completed | — | — | — |
NCT00365365CT.gov Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | — | Completed | — | — | — |
NCT00429299CT.gov Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | — | Completed | — | — | — |
NCT00589901CT.gov An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC) | — | Unknown | — | — | — |
NCT00436709CT.gov Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | — | Unknown | — | — | — |
NCT00499083CT.gov Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | — | Completed | — | — | — |
NCT00407888CT.gov Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | — | Completed | — | — | — |
NCT00376805CT.gov Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00616122CT.gov Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00258960CT.gov Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00331552CT.gov Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00310089CT.gov AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00254592CT.gov Neoadjuvant Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00425672CT.gov ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | — | Completed | — | — | — |
NCT00127933CT.gov XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00296010CT.gov Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer | — | Terminated | — | — | — |
NCT00182793CT.gov Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00203372CT.gov Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | — | Completed | — | — | — |
NCT00286819CT.gov Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer | — | Completed | — | — | — |
NCT00591851CT.gov Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | — | Completed | — | — | — |
NCT00095862CT.gov Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | — | Terminated | — | — | — |
NCT00617370CT.gov Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | — | Completed | — | — | — |
NCT00293384CT.gov Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | — | Completed | — | — | — |
NCT00206518CT.gov Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | — | Completed | — | — | — |
NCT00427245CT.gov Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00196872CT.gov A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) | — | Completed | — | — | — |
NCT00665457CT.gov Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | — | Terminated | — | — | — |
NCT00256243CT.gov Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00129896CT.gov Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | — | Completed | — | — | — |
NCT00309920CT.gov Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | — | Unknown | — | — | — |
NCT00093834CT.gov Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00148668CT.gov Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00068601CT.gov S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer | — | Completed | — | — | — |
NCT00311636CT.gov Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00146562CT.gov Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | — | Completed | — | — | — |
NCT00228358CT.gov Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine | — | Completed | — | — | — |
NCT00049114CT.gov Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00053911CT.gov Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | — | Terminated | — | — | — |
NCT00544765CT.gov Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer | — | Completed | — | — | — |
NCT00052351CT.gov Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00089479CT.gov A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00544232CT.gov Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | — | Completed | — | — | — |
NCT00352378CT.gov Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer | — | Completed | — | — | — |
NCT00206466CT.gov Biologic Correlative Taxotere/AC | — | Completed | — | — | — |
NCT02748213CT.gov A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00795899CT.gov Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | — | Completed | — | — | — |
NCT00206453CT.gov Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT01222052CT.gov 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT00312208CT.gov Docetaxel in Breast Cancer | — | Completed | — | — | — |
NCT00027807CT.gov Biological Therapy in Treating Women With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00047099CT.gov Combination Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00148681CT.gov Preoperative Herceptin and Navelbine for Breast Cancer | — | Completed | — | — | — |
NCT00016276CT.gov Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT00014222CT.gov Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00006123CT.gov Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00020176CT.gov Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
NCT00006261CT.gov Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer | — | Withdrawn | — | — | — |
NCT00668616CT.gov Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes | — | Completed | — | — | — |
NCT00647218CT.gov Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00022230CT.gov Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | — | Withdrawn | — | — | — |
NCT00012311CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer | — | Unknown | — | — | — |
NCT00004172CT.gov Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00004174CT.gov Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00004900CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00004906CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00003927CT.gov Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00206505CT.gov Neoadjuvant Taxotere | — | Completed | — | — | — |
NCT00003638CT.gov Vaccine Therapy in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00003680CT.gov Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | — | Unknown | — | — | — |
NCT00004237CT.gov Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer | — | Completed | — | — | — |
NCT00003877CT.gov Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00003972CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | — | Completed | — | — | — |
NCT00003893CT.gov Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer | — | Completed | — | — | — |
NCT00003352CT.gov Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003269CT.gov Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00003425CT.gov Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | — | Completed | — | — | — |
NCT00003199CT.gov Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003068CT.gov High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003042CT.gov Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00002967CT.gov Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00003032CT.gov High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT00003086CT.gov Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00590785CT.gov Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | — | Completed | — | — | — |
NCT00152178CT.gov The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) | — | Completed | — | — | — |
NCT00002772CT.gov S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | — | Terminated | — | — | — |
NCT00002784CT.gov High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00002780CT.gov Biological Therapy in Treating Women With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00008203CT.gov Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00019084CT.gov Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00002755CT.gov Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00002836CT.gov Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer | — | Completed | — | — | — |
NCT00005798CT.gov Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00002616CT.gov Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT00002870CT.gov High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00002628CT.gov Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00002627CT.gov Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | — | Unknown | — | — | — |
NCT00001384CT.gov A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | — | Completed | — | — | — |
NCT00002680CT.gov Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00002582CT.gov Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer | — | Completed | — | — | — |
NCT00002580CT.gov Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer | — | Completed | — | — | — |
NCT00002498CT.gov Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT00060255CT.gov High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00002509CT.gov High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer | — | Completed | — | — | — |
NCT00002475CT.gov Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00309478CT.gov Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | — | Completed | — | — | — |
NCT00929591CT.gov SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer | — | Completed | — | — | — |
NCT00793377CT.gov Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Fudan University | Approved | BB · 69 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Carboplatin | Akeso | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cyclophosphamide in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →